A recommended practical approach to the management of anthracycline-based chemotherapy cardiotoxicity
Paolo Spallarossa(Ospedale Policlinico San Martino), Giuseppe Mercuro(University of Cagliari), Donato Mele(University of Ferrara), Alessia Pepe(Fondazione Toscana Gabriele Monasterio), Pasquale Pagliaro(Ospedale San Luigi Gonzaga), Ines Monte(University of Catania), Concetta Zito(University of Messina), Carlo G. Tocchetti(Federico II University Hospital), Nicola Maurea(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Giuseppina Novo(AOL (United States)), Rosalinda Madonna(University of Chieti-Pescara)
Cited by 52
Related Papers
2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)
|European Heart Journal|2022|2.7k
Baseline Cardiovascular Risk Assessment in Cancer Patients Scheduled to Receive Cardiotoxic Cancer Therapies: A Position Statement and New Risk Assessment Tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in Collaboration with the International Cardio-Oncology Society
|European Journal of Heart Failure|2020|767
2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS)
|European Heart Journal - Cardiovascular Imaging|2022|486
Role of Cardiovascular Imaging in Cancer Patients Receiving Cardiotoxic Therapies: A Position Statement on Behalf of the Heart Failure Association (HFA), the European Association of Cardiovascular Imaging (EACVI) and the Cardio-Oncology Council of the European Society of Cardiology (ESC)
|European Journal of Heart Failure|2020|364